

Bevacizumab GOG-0218

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Bevacizumab GOG-0218

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
Therapeutic Indication: Front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Experimental Arm: Bevacizumab + Carboplatin + paclitaxel
Control Arm: Paclitaxel + carboplatin (6 cycles)

